Investor Relations

Our Mission

Developing transformative medicines to improve the lives of patients with Central Nervous System (CNS) disorders.

What drives us

We pursue rigorous science, transparent communication, and meaningful partnerships with patients, caregivers, clinicians, and research collaborators.

Advancing novel treatments for serious CNS disorders

Filana Therapeutics is a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and potentially other indications. Simufilam is a proprietary, investigational oral small molecule believed to modulate activity of the filamin A (FLNA) protein, which regulates diverse aspects of neuronal development. Studies conducted in the lab of Dr. Angélique Bordey at Yale School of Medicine provide the foundation for developing simufilam as a therapy for TSC and other mTOR pathway disorders. In a mouse model of focal onset seizures due to TSC-related pathology, the Bordey lab showed that treating mice with simufilam, before or after seizure onset, reduced seizure frequency by 60% compared to vehicle-treated mice. More recently, a study in a TSC mouse model conducted with the TSC Alliance’s Preclinical Consortium showed that simufilam attenuated the progression of seizure activity in a dose-dependent manner, supporting planning a clinical study.